Laekna, Inc. (2105.HK), a global biotech company focused on developing novel therapies for metabolic and cancer diseases, is excited to announce a clinical collaboration with Eli Lilly and Company (Lilly), a leader in cardiometabolic health, including diabetes and obesity. The collaboration aims to accelerate the development of LAE102, a novel ActRIIA monoclonal antibody, as a potential treatment for obesity. This partnership seeks to advance innovative treatments that could significantly impact the obesity epidemic and improve the lives of millions affected by the condition.
Key highlights of the collaboration include:
- Clinical development of LAE102 through a Phase 1 study involving obese patients
- Lilly will provide funding, resources, and expertise to expedite research and development timelines
- Laekna retains global rights to LAE102
The focus of the collaboration will be on the development and clinical evaluation of LAE102, an innovative ActRIIA antagonistic monoclonal antibody (mAb) with potential as a first-in-class therapy for obesity. ActRIIA is a receptor critical for muscle regeneration and lipid metabolism. Preclinical studies have shown that LAE102 increases lean mass and decreases fat mass. If successful, LAE102, when combined with a GLP1R agonist, could further reduce fat mass and significantly restore lean mass loss caused by GLP1R agonists, positioning it as a promising complementary treatment for effective weight control.
By combining Laekna’s innovative approach with Lilly’s extensive experience in metabolic diseases, the collaboration aims to elevate the standard of care in obesity management.
“We are excited to partner with Lilly, a global leader in obesity and metabolic diseases, to bring this groundbreaking treatment to patients suffering from this debilitating condition,” said Dr. Chris Lu, Chairman and CEO of Laekna. “With Lilly’s expertise in the cardiometabolic space, we are confident that this collaboration will accelerate the global development of LAE102 and improve the lives of millions affected by obesity.”
Lilly will leverage its Catalyze360-ExploR&D engine to drive the development of LAE102.
About LAE102
LAE102 is Laekna’s internally developed monoclonal antibody targeting ActRIIA, a receptor involved in muscle regeneration and lipid metabolism. In preclinical models, LAE102 has been shown to increase lean mass and reduce fat mass. When combined with a GLP1R agonist, LAE102 can further reduce fat mass and help restore the lean mass lost due to the agonist, making it a potential candidate for effective weight control.
Blocking the Activin-ActRII pathway has the potential to promote muscle regeneration and decrease fat mass. Laekna is also developing additional drug candidates, including LAE103 (an ActRIIB-selective antibody) and LAE123 (a dual inhibitor for ActRIIA/IIB), to maximize the therapeutic potential of targeting ActRII receptors.
About Laekna
Laekna, founded in 2016, is a science-driven, clinical-stage biotechnology company dedicated to developing innovative therapies for cancer, metabolic diseases, and liver fibrosis. Laekna has initiated multiple clinical trials for LAE102, LAE002 (afuresertib), LAE001, and LAE005, addressing unmet needs in obesity and cancer treatment.
Laekna’s pipeline includes LAE102, an internally discovered antibody targeting ActRIIA, which has shown promising preclinical results in promoting muscle regeneration and reducing fat mass. The company has received IND approvals for LAE102 in obesity and is advancing Phase 1 clinical trials in China.
In cancer research, Laekna has developed a comprehensive portfolio of drug candidates targeting breast cancer, prostate cancer, ovarian cancer, and PD-1/PD-L1-resistant solid tumors. LAE002 (afuresertib), an AKT inhibitor, is one of the few AKT inhibitors in late-stage development for breast and prostate cancer. Laekna has initiated a Phase III trial (AFFIRM-205) for LAE002 in HR+/HER2- breast cancer.
Laekna was listed on the Hong Kong Stock Exchange (2105.HK) on June 29, 2023.
